Several potential immunotherapy target agents, including anti-CTLA4, anti-PD-1/PD-L1, cancer vaccines, and adoptive cell therapy, have become prominent in immunotherapy-based clinical trials for GC. The gene discussed is PDCD1; the disease is cancer.